CIK 0000914475
- Large accelerated filer
NEUROCRINE BIOSCIENCES INC
Sign in to watch- Ticker
- NBIX
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 330525145
- Phone
- +1 858-617-7600
- Business address
- 6027 EDGEWOOD BEND COURT, SAN DIEGO, CA, 92130
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $3,162,347
- in 4 filings, $3.2M under 10b5-1 plans
Net −$3,162,347. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2021-02-08 | Lloyd-Smith Malcolm Chief Regulatory Officer | Sale | −1,015 | $116.87 | $119K | 32,510 |
| 2021-02-08 | Lloyd-Smith Malcolm Chief Regulatory Officer | Grant or award · Stock Option | +31,880 | 31,880 | ||
| 2021-02-08 | Lloyd-Smith Malcolm Chief Regulatory Officer | Grant or award · Restricted Stock Unit | +5,314 | 5,314 | ||
| 2021-02-08 | Grigoriadis Dimitri E. Chief Research Officer | Sale | −687 | $116.67 | $80K | 83,456 |
| 2021-02-08 | Grigoriadis Dimitri E. Chief Research Officer | Sale | −803 | $116.69 | $94K | 84,178 |
| 2021-02-08 | Grigoriadis Dimitri E. Chief Research Officer | Sale | −1,218 | $116.70 | $142K | 85,273 |
| 2021-02-08 | Grigoriadis Dimitri E. Chief Research Officer | Grant or award · Stock Option | +38,256 | 38,256 | ||
| 2021-02-08 | Grigoriadis Dimitri E. Chief Research Officer | Grant or award · Restricted Stock Unit | +6,376 | 6,376 | ||
| 2021-02-08 | GORMAN KEVIN CHARLES Chief Executive Officer | Sale | −2,875 | $116.79 | $336K | 446,144 |
| 2021-02-08 | GORMAN KEVIN CHARLES Chief Executive Officer | Sale | −4,343 | $116.74 | $507K | 450,051 |
| 2021-02-08 | GORMAN KEVIN CHARLES Chief Executive Officer | Sale | −3,248 | $116.71 | $379K | 452,972 |
| 2021-02-08 | GORMAN KEVIN CHARLES Chief Executive Officer | Grant or award · Stock Option | +103,609 | 103,609 | ||
| 2021-02-08 | GORMAN KEVIN CHARLES Chief Executive Officer | Grant or award · Restricted Stock Unit | +17,269 | 17,269 | ||
| 2021-02-05 | Gano Kyle Chief Business Development Off | Sale | −703 | $113.77 | $80K | 98,663 |
| 2021-02-05 | Gano Kyle Chief Business Development Off | Sale | −1,974 | $114.09 | $225K | 100,439 |
| 2021-02-05 | Bozigian Haig P. Chief Development Officer | Sale | −704 | $113.79 | $80K | 153,328 |
| 2021-02-05 | BENEVICH ERIC Chief Commercial Officer | Sale | −809 | $114.03 | $92K | 16,434 |
| 2021-02-05 | Cooke Julie Chief Human Resources Officer | Sale | −605 | $113.86 | $69K | 12,125 |
| 2021-02-05 | Lloyd-Smith Malcolm Chief Regulatory Officer | Sale | −865 | $114.15 | $99K | 29,675 |
| 2021-02-05 | Grigoriadis Dimitri E. Chief Research Officer | Sale | −605 | $113.76 | $69K | 82,169 |
Page 61 of 62 · 1,221 trades